Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-25 @ 2:40 AM
NCT ID:
NCT03122834
Eligibility Criteria:
Inclusion Criteria:
* Heart failure patients NYHA class II to IV.
* Left ventricular ejection fraction (LVEF) \< 45%
* Written informed consent of the subject to participate in the study.
* Newly diagnosed patients who will be treated with BBs and ACEIs/or ARBs.
* Patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
* Age of 18 years to 80 years.
Exclusion Criteria:
* Contraindication to SGLT2i.
* Contraindication to Spironolactone / Eplerenone.
* Patients who received previous treatment with Spironolactone / Eplerenone.
* Sig CAD, CABG, PCI, or valve surgery within 3 months.
* Mild-to-severe valvular stenosis or severe (grade III/IV) valvular regurgitation
* Pregnant or nursing women.
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT03122834
Study Brief:
Protocol Section:
NCT03122834